Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CBFA2T3
REST API REST API
Homo sapiens
CBFA2T3 is differentially expressed in 212 experiments: 87 organism parts: cerebellum, thymus, ... (85 more);, 158 disease states: normal, control, ... (156 more);, 78 cell types 324 cell lines 24 compound treatments and 62 other conditions.
Synonyms MTG16, ZMYND4, MTGR2
Orthologs CBFA2T3 (Bos taurus)   CBFA2T3 (Danio rerio)   Cbfa2t3 (Mus musculus)   Cbfa2t3 (Rattus norvegicus)   CBFA2T3 (Gallus gallus)   nvy (Drosophila melanogaster)   cbfa2t3 (Xenopus laevis)   CBFA2T3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, cell proliferation, intracellular, membrane, Golgi membrane, Golgi apparatus, metal ion binding, cell differentiation, positive regulation of transcription from RNA polymerase II promoter, nucleus, chromatin binding, nucleoplasm, nucleolus, zinc ion binding, granulocyte differentiation, sequence-specific DNA binding transcription factor activity
InterPro Term Znf_MYND, MTG16, ETO, TAFH_NHR1, NHR2
UniProt Accession O75081, B3KR45, E7EU24
Search EB-eye ENSG00000129993
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (28 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MCF7
2
E-GEOD-5258, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
SW620
2
E-MEXP-1014, E-MTAB-37
T47D
2
E-MEXP-440, E-MTAB-62
318 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (36 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-19069
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
testis - germ cell
2
E-AFMX-5, E-TABM-145
lymphoid
1
E-GEOD-19069
72 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (52 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-GEOD-2514, E-MTAB-62
multiple myeloma
3
E-MTAB-62, E-GEOD-6691, E-GEOD-2113
control
1
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-16728, E-GEOD-20602
neuroblastoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
Burkitt's lymphoma
1
2
E-GEOD-1880, E-MTAB-37, E-GEOD-96
152 more value(s).


Compound treatment

studied in E-TABM-782, E-TABM-868, E-GEOD-15811, E-GEOD-5099, E-GEOD-6462, ... (18 experiments)

Factor Value U/D Experiments
none
3
6
E-TABM-782, E-TABM-868, E-MEXP-1958, E-GEOD-1740, E-GEOD-412, ... (9 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
saline
1
E-GEOD-3026
BCR/FGFR1
1
E-GEOD-15811
Cxcl12
1
E-GEOD-7307
PGE2
1
E-MEXP-1230
18 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-19246, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-19665, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-12773, E-MEXP-1446, E-MEXP-2146

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (24 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460 ... (5 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-19246, E-GEOD-15799

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.438 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM